Back to search
dTap Vaccine
Clinical trial pipeline · Data from ClinicalTrials.gov
See which dTap Vaccine trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which dTap Vaccine trials you may qualify forThe goal of this clinical study is to compare the immunogenicity and safety of one dose of sIPV in adolescents or adults aged 7-50 years with that of three dose…
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two u…
This is a phase IV, open-label, non-randomized study to demonstrate superior immunogenicity and safety of a second booster dose of Pertagen® as compared to Adac…
The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Ag…
The purpose of this study is to evaluate the safety and immunogenicity of the DTaP in 3-month-old infants.
Primary objectives: To investigate the incidence of adverse events occurred following administration of Hexaxim in infants from 2 months of age under routine c…
This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents. The purposes of this study are as fol…